Chang AY - Search Results

1

Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer.

Zhang X, Zhao Y, Wang M, Yap WS, Chang AY. Zhang X, et al. Among authors: chang ay. Lung Cancer. 2008 May;60(2):175-82. doi: 10.1016/j.lungcan.2007.10.011. Epub 2007 Dec 3. Lung Cancer. 2008. PMID: 18061305

2

Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer.

Zhang X, Chang A. Zhang X, et al. Int J Med Sci. 2008 Jul 11;5(4):209-17. doi: 10.7150/ijms.5.209. Int J Med Sci. 2008. PMID: 18645621 Free PMC article. Review.

3

Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.

Zhang X, Chang A. Zhang X, et al. J Med Genet. 2007 Mar;44(3):166-72. doi: 10.1136/jmg.2006.046102. Epub 2006 Dec 8. J Med Genet. 2007. PMID: 17158592 Free PMC article. Review.

4

In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.

Chang AY, Wang M. Chang AY, et al. Anticancer Drugs. 2013 Mar;24(3):251-9. doi: 10.1097/CAD.0b013e32835ba289. Anticancer Drugs. 2013. PMID: 23187461

5

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P. Lim EH, et al. J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28. J Thorac Oncol. 2009. PMID: 19096301 Free article.

6

Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.

Chang A. Chang A. Lung Cancer. 2011 Jan;71(1):3-10. doi: 10.1016/j.lungcan.2010.08.022. Epub 2010 Oct 16. Lung Cancer. 2011. PMID: 20951465 Review.

7

Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.

Chang AY, Wang M. Chang AY, et al. BMC Cancer. 2013 May 30;13:267. doi: 10.1186/1471-2407-13-267. BMC Cancer. 2013. PMID: 23721490 Free PMC article.

8

Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.

Chang A, Parikh P, Thongprasert S, Tan EH, Perng RP, Ganzon D, Yang CH, Tsao CJ, Watkins C, Botwood N, Thatcher N. Chang A, et al. J Thorac Oncol. 2006 Oct;1(8):847-55. J Thorac Oncol. 2006. PMID: 17409969 Free article. Clinical Trial.

9

The role of gefitinib in the management of Asian patients with non-small cell lung cancer.

Chang AY. Chang AY. Expert Opin Investig Drugs. 2008 Mar;17(3):401-11. doi: 10.1517/13543784.17.3.401. Expert Opin Investig Drugs. 2008. PMID: 18321238 Review.

10

Differential reactions of microglia to brain metastasis of lung cancer.

He BP, Wang JJ, Zhang X, Wu Y, Wang M, Bay BH, Chang AY. He BP, et al. Among authors: chang ay. Mol Med. 2006 Jul-Aug;12(7-8):161-70. doi: 10.2119/2006–00033.He. Mol Med. 2006. PMID: 17088948 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

600 results

Search Page

Filters